Table 2 Key clinical parameters of each patient from the BeGIN study, in which tissue sections were stained with pan-cytokeratin,α-SMA and CD68
Patient ID | Sex | Age | BMI | Histology | Pathological stage | Histological tumour grade |
|---|---|---|---|---|---|---|
SGH001 | F | 58 | 25.6 | ER+/PR+/HER2− | T1N0 | 1 |
SGH005 | F | 59 | 30.1 | ER+/PR+/HER2− | T1N0 | 2 |
SGH006 | F | 72 | 24.3 | ER−/PR−/HER2− | T1N0 | 2 |
SGH007 | F | 57 | 30.8 | ER+/PR+/HER2− | T1N0 | 2 |
SGH008 | F | 69 | 27.6 | ER+/PR+/HER2− | T2N1 | 3 |
SGH010 | F | 48 | 30.5 | ER+/PR+/HER2− | T2N0 | 3 |
SGH013 | F | 55 | 28.6 | ER−/PR−/HER2− | T2N0 | 2 |
SGH014 | F | 55 | 36.1 | ER+/PR+/HER2− | T1N0 | 2 |
SGH015 | F | 52 | 20.2 | ER+/PR+/HER2− | T1N0 | 1 |
SGH016 | F | 68 | 28.6 | ER+/PR+/HER2− | T2N1 | 2 |
SGH018 | F | 72 | 23.2 | ER+/PR+/HER2− | T1N0 | 2 |
SGH021 | F | 69 | 29.3 | ER−/PR−/HER2− | T2N0 | 1 |
SGH022 | F | 63 | 17.8 | ER+/PR+/HER2− | T1N1 | 2 |
SGH023 | F | 58 | 35.8 | ER−/PR−/HER2− | T1N0 | 2 |
SGH097 | F | 73 | 29.8 | ER−/PR−/HER2− | T2N0 | 3 |
SGH101 | F | 40 | 25.2 | ER−/PR−/HER2− | T2N1 | 3 |
SGH106 | F | 41 | 20.5 | ER−/PR−/HER2− | T1N0 | 3 |
SGH108 | F | 66 | 38.3 | ER−/PR−/HER2− | T1N0 | 3 |
SGH149 | F | 64 | 25.5 | ER−/PR−/HER2− | T2N1 | 2 |
SGH158 | F | 47 | 50.8 | ER−/PR−/HER2− | T1N0 | 3 |
